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Abstract
Background Little comparative evidence is available on
utilisation of cancer medicines in different countries and its
determinants. The aim of this study was to develop a sta-
tistical model to test the correlation between utilisation and
possible determinants in selected European countries.
Methods A sample of 31 medicines for cancer treatment
that obtained EU-wide marketing authorisation between
2000 and 2012 was selected. Annual data on medicines’
utilisation covering the in- and out-patient public sectors
were obtained from national authorities between 2008 and
2013. Possible determinants of utilisation were extracted
from HTA reports and complemented by contacts with key
informants. A longitudinal mixed effect model was fitted to
test possible determinants of medicines utilisation in Bel-
gium, Scotland and Sweden.
Results In the all-country model, the number of indications
reimbursed positively correlated with increased consump-
tion of medicines [one indication 2.6, 95% CI (1.8–3.6);
two indications 2.4, 95% CI (1.4–4.3); three indications
4.9, 95% CI (2.2–10.9); all P\ 0.01], years since EU-wide
marketing authorisation [1.2, 95% CI (1.02–1.4);
p\ 0.05], price per DDD [0.9, 95% CI (0.998–0.999),
P\ 0.01], and Prescrire rating [0.5, 95% CI (0.3–0.9),
P\ 0.05] after adjusting for time and other covariates.
Conclusions In this study, the most important correlates of
increased utilisation in a sample of cancer medicines
introduced in the past 15 years were: medicines coverage
and time since marketing authorisation. Prices had a neg-
ative effect on consumption in Belgium and Sweden. The
positive impact of financial MEAs in Scotland suggests
that the latter may remove the regressive effect of list
prices on consumption.
Keywords Medicines utilisation  Multilevel mixed-
effects data models  Oncology  Managed entry
agreements  Pharmaceutical policy
JEL Classification I10  I14
Introduction
Managing the introduction of new, high-priced cancer
medicines is a challenge for countries at all levels of
development. On the one side, payers want to provide
access to new and potentially more effective medicines,
while on the other they need to ensure the financial sus-
tainability of their health care systems, value for money
and an equitable distribution of the available resources.
In Europe, decisions regarding the reimbursement of
new high cost medicines are increasingly made using
health technology assessment (HTA). While important
differences exist in the way individual countries implement
HTA, they all include in their analysis and decision-making
process information on the efficacy and effectiveness and,
to different extents, information on the price of the new
medicine. This technique not only enables to determine the
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cost-effectiveness of a medicine according to the licensed
indication, it can also help identifying the patient subgroup
in which the medicine is most cost-effective. Limiting
access to such a subgroup of patients is one tool countries
are using to manage the introduction of new medicines.
Another way to manage entry is to delay the assessment
of new medicines. This may be done with an explicit
rationing objective, it may be caused by the time involved
in conducting HTA but it may also be due to the lack of
submission of a pricing and reimbursement dossier by the
manufacturer. These factors can lead to a medicine not
being reimbursed at all in a particular country, or to
reimbursement being limited to a subset of all licensed
indications. Lack of a national level positive decision on
reimbursement, or lack of a legal requirement to implement
such a decision at local level, can lead to disparities in
availability of the medicine for patients within countries. In
this context, local authorities or hospitals will decide
whether or not to fund the medicine, and could possibly
lead to no availability at all.
Increasingly, countries are using managed entry agree-
ments (MEAs) to facilitate access while trying to limit
budget impact and improve cost-effectiveness in a context
of uncertainty [1–3]. The way medicines are financed also
has an impact on access, and can influence their uptake.
Availability of top-up funding for new high cost medicines
can incentivise prescribing and use over medicines that are
funded by hospital budgets. The effect of prospective
payment systems like diagnostic-related groups is most
likely dependent on their design [4]. Special funds ear-
marked for particular products have been established in
some countries. Examples include the cancer drugs fund in
England [5], the risk-share scheme for orphan medicines,
the rare disease fund in Scotland [6, 7], and the rare disease
fund in Belgium [8]. The latter aim to increase availability
of high cost medicines that may otherwise be unavailable
or whose financing would cause individual institutions
financial difficulties.
The setting—ambulatory or hospital—where the medi-
cine is prescribed and dispensed can determine whether a
co-payment applies or not, and potentially influence levels
of utilisation too. While co-payments for cancer medicines
(particularly when these medicines are dispensed in hos-
pitals) are not common in Western European countries,
their use and the extent of cost-sharing may influence
utilisation. In some countries, third party payers may
require prescribing doctors to obtain prior authorisation by
a physician designated by the payer, before the medicine
can be prescribed.
Beyond pricing and reimbursement, disease burden,
demographics, access to timely diagnosis, clinical practice,
access to specialist care, whether the disease is a national
priority, and cultural factors including defensive medicine
also have an impact on use of new high priced medicines
and may lead to differential uptake across countries [9–13].
While the factors influencing access and use of cancer
medicines have, to a certain extent, been identified and
discussed in the literature, less evidence is available on
the actual levels of cancer medicine consumption across
different countries, and, most importantly, their
determinants.
Differences in the use of cancer medicines between
selected high income countries have been investigated in
an international study on medicine use in 2008/2009 and its
update in 2013/2014 [9, 14]. A study on endocrine thera-
pies for breast cancer investigated patterns of use in eight
western European countries plus Australia over the period
2001–2012 [15]. A series of comparative longitudinal
studies on patient access to cancer medicines in Europe
have been conducted covering the time period from 1993
to 2014. These studies looked at differences in expenditure
and, for selected medicines, also milligrams or grams per
case, and defined daily doses per case [16–18]. Possible
determinants of utilisation differences or lack of differ-
ences have been investigated using a qualitative approach
(benchmarking possible determinants against quantitative
data) [9, 15, 19, 20]. A study on utilisation of orphan
medicines vs. non-orphan medicines used the t test to
assess whether an association existed between orphan
medicine status and variability in use across countries [21].
Some correlation analysis was conducted in the 2016
update of the study on uptake of oncology medicines in
Europe, which noted that uptake of innovative medicines
depends largely on the country’s gross domestic product,
and the level of health care spending per capita [18].
However, the authors also noted that differences in use
across countries with similar economic status exist [18].
Reasons for the limited number of studies analysing con-
sumption of cancer medicines data particularly those
applying statistical methods are likely to include, but are
not limited to, the difficulties in accessing data on
medicines dispensed in hospitals from public sources, and
the cost of accessing from private ones. Furthermore, it can
be difficult, and sometimes impossible, to assign a
numerical value to all possible determinants of use to test
as part of a statistical model.
The aim of this study was therefore to test the correla-
tion between utilisation of cancer medicines (mostly dis-
pensed in hospital settings) and possible determinants of
utilisation of cancer medicines in selected European
countries. The study contributes to the existing literature by
providing updated longitudinal evidence on consumption
of cancer medicines in Europe, and by developing a lon-
gitudinal multilevel model to test the correlation between
utilisation and likely determinants adjusting for important
covariates.
A. Ferrario
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Methods
Sample selection and variable definition
Three countries were selected based on access to data from
public sources: Belgium, Scotland and Sweden. Despite the
convenience nature of the sample, the three countries
represent a suitable study group due to their geographical
location (Western Europe), similar gross domestic product
and spending on health per capita levels, health system
organisation (comprehensive universal health coverage
system), and a population size ranging from more than 5
million to 11 million inhabitants in 2013 (Supplementary
Data, SD1).
Using the anatomic therapeutic chemical (ATC)
search function for European Public Assessment Reports
available from the website of the European Medicines
Agency (EMA), all antineoplastic (ATC-L01) and
endocrine (ATC-L02) medicines authorised in the Euro-
pean Union (EU) and the European Economic Area
countries (Iceland, Liechtenstein and Norway) were
identified. Medicines that were withdrawn post-approval,
suspended or refused were not included. The unified list
(ATC-L01 and L02) contained 106 medicines (different
brand names). I selected all medicines that obtained
EU-wide marketing authorisation between 2000 and 2012
(total 76). In an attempt to have a homogenous, yet
sufficiently large, sample (at least 30 medicines), I
excluded generics (17), orphan medicines (as classified
by EMA at the time of data extraction) (19), biosimilars
(zero) and medicines approved under exceptional cir-
cumstances (zero after excluding orphans) since uptake
of these medicines is likely to be influenced by different
factors than for the majority of other medicines included.
There were five medicines approved with a conditional
marketing authorisation in the remaining sample of 40
medicines. I excluded five medicines that were new
brands of international non-proprietary names (INNs)
approved before 2000. Finally, after extracting data on
consumption from the three study countries, I excluded
four medicines for which there was no consumption
during the study period (2008–2013) in two or more
study countries. The final sample of medicines (different
INNs) included in the analysis was 31 (Supplementary
Data, SD2) (Fig. 1).
Although the subject matter of this study was cancer, I
did not include immunostimulant medicines (ATC-L03)
because only some of these medicines are indicated for
cancer treatment. Further, even if a medicine is indicated
for the treatment of cancer, the other indications may not
be and the data did not allow to disaggregate medicines use
by indication.
Data sources
Quantitative (e.g. mg of medicines dispensed, date of reim-
bursement for the first indication) and qualitative (e.g. pos-
itive vs. negative reimbursement decision, implementation
of MEAs) data were used to build the statistical model. Data
on medicines utilisation (pack size, number of packs,
strength per quarter or month) in ambulatory and hospital
settings by INN and brand (Belgium and Sweden) and by
INN only (Scotland) between 2008 and 2013 was obtained
from the National Institute for Health and Disability Insur-
ance (INAMI-RIZIV) in Belgium, the Dental and Pharma-
ceutical Benefits Agency (TLV) and eHa¨lsomyndigheten in
Sweden and the National Health Service (NHS) in Scotland.
The list of MEAs for each country was sourced from a pre-
vious study for Belgium and Sweden [3] and the Scottish
Medicines Consortium website for Scotland [22]. Prices per
defined daily dose (DDD) were estimated from expenditure
data provided by INAMI-RIZIV in Belgium and TLV and
eHa¨lsomyndigheten in Sweden, and using historical prices
from the British National Formulary in Scotland. DDDs from
the Belgian Centre of Pharmacotherapeutic Information [23]
were used since the ATC/DDD Index of the WHO Collab-
orating Centre for Drug Statistics Methodology does not
define DDDs for most cancer medicines.
Additional data on the study variables was extracted
from the websites of national competent authorities (e.g.
HTA reports and ministerial decisions) [24–26], personal
contacts with these authorities or clinicians, and from the
utilisation data provided by the countries.
The variables extracted included the date when a posi-
tive reimbursement decision (Belgium and Sweden) or
positive recommendation for use (Scotland) for the first
indication of a medicine was made, the number of indi-
cations (measured as different types of cancer) covered or
recommended for use in each of the study years, use and
type of a MEA, setting where the medicine was dispensed
and patient co-payments.
While decisions in Belgium and Sweden—relate to
reimbursement and in Scotland they relate to use within the
national health system, for the sake of simplicity the term
used henceforth is ‘reimbursement’ or ‘coverage’. In
Sweden, a reimbursement decision is usually made by TLV
for outpatient medicines and by the county councils (the
latter, in recent years were increasingly made through the
NT-council, a body representing all the county councils)
for hospital medicines. Some medicines are not assessed by
any of these two bodies but recommended as part of
national guidelines. National guidelines aimed at support-
ing resource allocation decisions are developed by the
National Board of Health and Welfare (NBHW), these are
not clinical guidelines but can and are also used as clinical
Determinants of utilisation differences for cancer medicines in Belgium, Scotland and Sweden
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guidelines. Further, since 2011, national guidelines on
breast, prostate, colorectal and lung cancer are developed
by professional organisations under the regional cancer
centre. Before 2011, each professional group was respon-
sible for cancer care programmes. I therefore checked
guidance by the NBHW, the regional cancer centre, and
contacted clinicians responsible for the cancer care pro-
grammes before 2011.
Data analysis
The study included a total of nine independent variables.
This includes six continuous variables, notably (1) the
number of years since a medicine obtained EU-wide
marketing authorisation for the first indication; (2) the
number of years since a positive reimbursement decision
was awarded for the first indication; (3) the median price
per DDD; (4) time (year 1–6); (5) total pharmaceutical
expenditure per 1000 capita and year (euros); and (6) the
average rating of clinical added value across all indica-
tions assessed by the independent Drug Bulletin Pre-
scrire (1–7, where 1 represents highest level of added
clinical value, 6 the lowest level, and 7 reserved judg-
ment due to insufficient evidence) [27]. Three
categorical variables are also included, namely (1) the
number of reimbursed indications (measured as different
types of cancer, 0–3); (2) the setting where the medicine
was dispensed (1 = hospital only, 2 = ambulatory only,
3 = both); and (3) use of a MEA (1 = no MEA,
2 = health outcome based MEA, 3 = financial,
4 = combination), which were modelled as dummies.
The all country model included also dummy variables
for countries, and interaction terms between countries
and time.
I used DDDs per 1000 population to measure utilisation
of cancer medicines. In order to compute the total number
of DDDs consumed, I calculated the total mg of active
ingredient dispensed for a particular INN. I used the DDD
defined by the Belgian Centre of Pharmacotherapeutic
Information [23] and divided the total mg by the Belgian
DDDs.
The resulting longitudinal data set was analysed in Stata
13 using the mixed command to allow for random slopes
[28]. To allow for non-linear increase in utilisation over
time, I used a non-linear polynomial function with t2 as an
additional predictor [29]. The between-medicines vari-
ability is treated as a random effect (i.e. as a random-in-
tercept term at the medicine level):
Fig. 1 Selection of cancer
medicines to be included in the
study
A. Ferrario
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yijk ¼ ajk þ bkXijk þ t þ t2 þ k þ t  k þ t2  k þ uj
þ vk þ eijk
where i year, j medicine and k country, Xijk is a vector of all
the independent variables included, uj is the medicine
specific random effect, vk is the country specific fixed
effect, and eijk is the error term.
Random effects model unobserved between-subject (in
this case medicines) variation as random, while fixed
effects model unobserved variation between subjects (in
this case countries) as constant [28]. Interactions allow for
differential increase (slope) between subjects. In this case
they allow for time to have a different effect on con-
sumption growth in each country. The logarithm of
medicines consumption was modelled because of non-
normal distribution of the non-transformed dependent
variable.
Results
Descriptive analysis
The median time since EU-wide marketing authorisation in
the sample was 5.6 years (N = 31 medicines, min
1.3 years, max 13.3 years) as of December 2013. At that
time, the median time since a positive reimbursement for
the first indication was made was 3.9 years (N = 30, min
0.45 years, max 10.5 years) in Belgium, 3.7 years
(N = 16, min 0.23, max 11.2) in Scotland and 4.2 years
(N = 21, min 0.1, max 12.7) in Sweden.
Some medicines had not been assessed by Scottish
Medicines Consortium (1) and neither TLV nor the NT-
council nor the NBHW nor professional bodies in Sweden
(9); other medicines were assessed and rejected (1 Bel-
gium, 12 Scotland and 1 Sweden) as of December 2013.
Until a few years ago, the adoption and utilisation of new
cancer medicines in Sweden used to be at the discretion of
the oncologists and their institutions. In the last few years,
national guidance has increasingly become available
through professional bodies, the NBHW, the NT and TLV.
Out of the total 31 INNs studied, Belgium recommended at
least one indication for 30 of them, Scotland 18 and
Sweden 21.
Belgium had the highest number of indications covered
(N = 39, 83% of total indications with EU-wide approval,
N = 47) as of December 2013, followed by Sweden
(N = 25, 53% of total) and Scotland (N = 19, 40% of
total) (Fig. 2). This does not mean that the other indications
were available only if the patient paid out-of-pocket, but
that there was no national level reimbursement decision.
Individual hospitals or local authorities may then decide to
make the medicine available to all or selected patients.
In Belgium, cancer medicines are fully reimbursed by
compulsory health insurance. Similarly, but not limited to
cancer medicines, there are no co-payments or charges on
prescription medicines in Scotland. In Sweden, prescrip-
tion medicines dispensed in hospitals are reimbursed at
100%, while prescription medicines dispensed in pharma-
cies are subject to a deductible plus a co-payment. Out-
patient-orders, when for example the primary care unit has
ordered a medicine and dispense it to the patient during the
consultation, are not subject to co-payments. Since there
were no co-payments in Belgium and Scotland and very
minimal co-payments in Sweden (maximum annual co-
payment for one year is about EUR 240 (SEK 2200) for all
medicines [30]), this variable was not included in the
statistical model.
Five, nine, and four medicines were part of a MEA in
Belgium, Scotland and Sweden, respectively. These
included five combination agreements in Belgium, eight
financial and one combination agreements in Scotland and
three combination and one health outcome agreements in
Sweden.
In all three countries, the largest volume share amongst
the medicines in the sample (measured as total number of
DDDs) was dispensed in hospital settings (including day
care units) in all years. In 2013, this share was highest in
Scotland (98%), followed by Belgium (74%) and Sweden
(66%). Sweden had the highest number of medicines dis-
pensed in both hospital and ambulatory settings (25), fol-
lowed by Belgium (6) and Scotland (4) (Fig. 3).
The following figures (Fig. 4) show medicines con-
sumption as the number of DDDs dispensed per 1000
population between 2008 (or the year when utilisation of
the medicine was first recorded) and 2013 by ATC-level 3
pharmacological subgroup. Belgium had the highest per
Fig. 2 Cumulative number of indications covered vs. approved
European Union (EU) indications (both measured as different types
of cancer)
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capita consumption of ‘other antineoplastic agents’
(L01X), the group to which most study medicines belong
(N = 23) in all years, while Sweden had the highest per
capita consumption of ‘hormone antagonist and related
agents’ (L02B) (N = 3), and ‘plant alkaloids and ana-
logues’ (L01C), (N = 2). Scotland, closely followed by
Sweden, had the highest per capita consumption of ‘an-
timetabolites’ (L01B) included in the study sample
(N = 3).
The median price per DDD was highest in Belgium
(EUR 116.5, min = EUR 2.9, max = EUR 3966.6), fol-
lowed by Sweden (EUR 90.3, min = EUR 2.4, max = -
EUR 2724.4), and lowest in Scotland (EUR 88.1, min 3.6,
max 5030.2).
The median Prescrire rating across all the 31 medicines
included in the study was 5, which corresponds to ‘nothing
new’. The medicine with the highest rating was imatinib
with a rating of 2, representing ‘a real advantage’, for four
Fig. 3 Settings where
medicines were dispensed by
share of defined daily doses
(DDDs) and number of
medicines
Fig. 4 Number of smallest units consumed per 1000 capita
A. Ferrario
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of the six indications evaluated. A number of medicines
(N = 11) had a Prescrire rating of 6, which stands for ‘not
acceptable’.
Statistical analysis: longitudinal mixed-effects model
In the all-country model, the number of indications reim-
bursed [one indication = 2.6, 95% CI (1.8–3.6); two
indications = 2.4, 95% CI (1.4–4.3); three indica-
tions = 4.9, 95% CI (2.2–10.9); all P\ 0.005], and the
number of years since marketing authorisation [1.2, 95%
CI (1.1–1.4), P value \0.05] positively correlated with
increased consumption of medicines after controlling for
time and other covariates (Table 1). Price per DDD [0.9,
95% CI (0.998–0.999), P value\0.05] and the low added
clinical value had a regressive effect on consumption [0.5,
95% CI (0.3–0.9), P value \0.05]. Having controlled for
time and country effects, no correlation was found with the
number of years since a positive reimbursement decision
for the first indication was given, the existence or not of
managed entry agreements, or the level (or the log) of total
pharmaceutical expenditure per 1000 capita.
Results for the country level models showed that the
following variables were positively correlated with
increased consumption: the number of disease areas cov-
ered in all countries, the number of years since EU-wide
marketing authorization in Scotland and Sweden, the use
of managed entry agreements in Scotland, and the setting
where the medicine was dispensed in Sweden. The vari-
ables that negatively influenced consumption were: the
price per DDD in Belgium and Sweden and the low value
of a medicine in Scotland (Table 2).
Discussion
Overall, Belgium and Sweden had the highest level of
consumption (measured as DDD/1000 capita) for non-or-
phan cancer medicines that obtained EU-wide marketing
authorisation between 2000 and 2012. Belgium had the
Table 1 All-country model
Exp (b) (95% CI) P value
Years since EU-wide marketing authorisation 1.202* 1.021 1.405 0.026
Years since positive reimbursement decision 0.998 0.980 1.015 0.795
Number of disease areas covered
1 2.599** 1.840 3.633 0.000
2 2.425* 1.377 4.259 0.002
3 4.904** 2.192 10.913 0.000
Use of managed entry agreements (baseline: no MEAs)
Health outcome MEA 0.962 0.393 2.627 0.933
Combination MEA 1.590 0.693 3.653 0.274
Financial MEA 1.539 0.831 2.852 0.171
Setting where the medicine is dispensed (baseline: hospital)
Ambulatory 0.460 0.156 1.368 0.163
Hospital and ambulatory 0.720 0.495 0.954 0.087
Price per DDD 0.999* 0.998 0.999 0.001
Prescrire rating 0.545* 0.337 0.881 0.013
Pharmaceutical expenditure per 1000 capita 1.000 1.000 1.000 0.837
Year 0.925 0.605 1.412 0.716
Year2 1.019 0.945 1.098 0.626
Country (baseline: Scotland)
Sweden 4.711* 0.343 57.111 0.034
Belgium 4.393 0.372 3.785 0.255
Sweden 9 year 1.185 0.593 1.896 0.772
Belgium 9 year 1.062 0.790 1.188 0.839
Sweden 9 year2 0.969 0.868 1.091 0.761
Belgium 9 year2 0.973 0.003 5469.815 0.642
Constant 3.896 1.000 1.000 0.712
EU European Union, MEA managed entry agreements, DDD defined daily dose, CI confidence interval
* P\ 0.05, ** P\ 0.001
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Table 2 Individual country models
Belgium Exp (b) (95% CI) P value
Years since EU-wide marketing authorisation 0.890 0.653 1.213 0.461
Years since positive reimbursement decision 1.284 0.900 1.833 0.168
Number of disease areas covered 1.000 1.000 1.000
1 2.648** 1.788 3.923 0.000
2 3.876** 2.119 7.090 0.000
3 6.802** 3.095 14.951 0.000
Use of managed entry agreements (baseline: no MEAs)
Combination MEA 1.043 0.389 2.797 0.934
Setting where the medicine is dispensed
Hospital and ambulatory 0.595 0.112 3.146 0.541
Price per DDD 0.998** 0.997 0.999 0.000
Prescrire rating 0.610 0.366 1.017 0.058
Pharmaceutical expenditure per 1000 capita 1.000 1.000 1.000 0.480
Year 1.049 0.744 1.481 0.784
Year2 0.972 0.916 1.033 0.363
Constant 1882.717 0.001 3,399,451,731.077 0.305
Sweden Exp (b) (95% CI) P value
Years since EU-wide marketing authorisation 1.361** 1.139 1.616 0.000
Years since positive reimbursement decision 0.902 0.787 1.034 0.140
Number of disease areas covered
1 2.316* 1.279 4.221 0.006
2 3.320 1.000 11.023 0.050
Use of managed entry agreements (baseline: no MEAs)
Health outcome MEA 3.287 0.826 13.197 0.091
Combination MEA 0.888 0.326 2.411 0.816
Setting where the medicine is dispensed
Ambulatory 0.519 0.174 1.537 0.238
Hospital and ambulatory 1.685* 1.048 2.713 0.031
Price per DDD 0.998** 0.954 2.691 0.000
Prescrire rating 0.784 0.522 1.174 0.242
Pharmaceutical expenditure per 1000 capita 1.000 1.000 1.000 0.103
Year 4.688 0.779 28.078 0.090
Year2 0.788 0.595 1.045 0.090
Constant 77652.576 0.044 140,363,314,266.971 0.125
Scotland Exp (b) (95% CI) P value
Years since EU-wide marketing authorisation 1.289* 1.115 1.490 0.001
Years since positive reimbursement decision 1.011 1.000 1.022 0.061
Number of disease areas covered
1 1.832 0.967 3.471 0.063
2 1.180 0.322 4.329 0.803
3 38.205** 2.395 609.506 0.010
Use of managed entry agreements (baseline: no MEAs)
Combination MEA 1.100 0.272 4.446 0.894
Financial MEA 3.249* 1.554 6.791 0.002
Setting where the medicine is dispensed
Hospital and ambulatory 1.174 0.602 2.288 0.638
Price per DDD 0.998 0.995 1.001 0.193
Prescrire rating 0.552* 0.367 0.832 0.004
Pharmaceutical expenditure per 1000 capita 1.000 1.000 1.000 0.710
A. Ferrario
123
highest absolute number of DDDs consumed per 1000
capita in 2012 and 2013. This does not seem to be
explained by the burden of disease, since Sweden has
generally a lower incidence rate than Belgium and Scotland
for a number of cancer (apart for melanoma), and Scotland
has the highest incidence among the three countries for a
number of cancers (e.g. breast, bronchus and lung, liver,
oesophagus, pancreas and stomach) (Supplementary Data,
SD3). In Sweden and Scotland, medicines used in hospitals
are financed through the hospital budget, and may be used
before a national level decision on reimbursement is made.
In contrast, in Belgium, with the exception of compas-
sionate use, pricing and reimbursement had to be com-
pleted before doctors could prescribe a medicine in hospital
settings as of December 2013. However, once this is
completed, hospital medicines are reimbursed separately
by INAMI and are not part of the fixed hospital budget.
This may explain why Belgium has higher per capita
consumption than Sweden between 2011 and 2013, and
generally a higher consumption than Scotland despite the
latter often having a higher disease burden.
The 2010 report to the United Kingdom (UK) Department
of Health used rankings to compare use of selected medici-
nes across various therapeutic areas among 14 OECD
countries in 2008/2009 [9]. An update of the 2010 report was
released in 2014 providing data for 2012/2013 [14]. The two
analyses included the UK and Sweden but not Belgium.
Although one cannot really compare the results of this study
to the UK study due to differences in the medicines included,
countries studied, and methods of analysis, one can at least
observe that utilisation of cancer medicines in Sweden was
usually higher than in Scotland in this study. In the
UK Department of Health study, Sweden ranked 9th in terms
of cancer medicines consumption and the UK ranked 10th
(with some differences within the cancer class, e.g. use of
endocrine therapies was higher in the UK than Sweden).
Further, this study confirms the importance of HTA out-
comes, included in the model as years since a positive
reimbursement decision was made and indications covered,
in determining levels of utilisation. This study also confirms
the absence of correlation between, in our case pharmaceu-
tical expenditure per capita, in the case of the report health
expenditure per capita, and utilisation.
The number of indications covered positively correlated
with increased consumption in all models although not all
levels of increase were significant. The effect was smallest
in Sweden possibly because before 2010, and, to a certain
extent still at the end of the study period (2014), decisions
on whether to fund or not a cancer medicine have been
made by the respective county councils in the absence of
national level guidance. Today there is increasing coordi-
nation in decision-making thanks to the centralisation of
cancer in six centres of excellence, and closer collaboration
between TLV and NT- council. The likely impact of cov-
erage decisions on prescribing and consumption was also
mentioned in a longitudinal study on endocrine therapies
[31], and the role of reimbursement and funding arrange-
ments for governing access to myeloma treatment in
England has been highlighted [32].
Time since EU-wide marketing authorisation had a
positive effect in all countries but Belgium. One explana-
tion could be that, in Belgium, reimbursement is a more
important factor than years since marketing authorisation.
Use in both hospital and ambulatory settings vs. hospital
only had a positive effect in Sweden, where it applies to
most medicines included in this study. Interestingly, the
price per DDD had a regressive effect in Belgium and
Sweden, but not in Scotland. One possible explanation for
the lack of negative impact of prices in Scotland may be
the implementation of MEAs (all with a financial compo-
nent for the medicines with MEA in this sample), which
off-set the high list price per DDD. Low value medicines
had a regressive effect on consumption in Scotland. The
2016 update of the study on the uptake of new cancer
medicines in Europe observed a correlation between the
European Society for Medical Oncology Magnitude of
Clinical Benefit Scale (ESMO-MCBS) and actual uptake;
however, this was not statistically significant, and the
number of medicines represented for most non-curative
score levels was very small (score 1, n = 0; score 2, n = 3;
score 3; n = 3, score 5, n = 1), only score 4 had 10
medicines represented [18].
Finally, it is worth noting that large differences in access
between and within country are not limited just to
medicines but, as shown by an analysis by the OECD, they
affect a number of medical procedures [33].
Not all possible determinants of utilisation of cancer
medicines are readily convertible into a numeric value that
can be tested as part of a statistical model. Examples
include cultural factors and clinical practice. Other
Table 2 continued
Scotland Exp (b) (95% CI) P value
Year 1.066 0.788 1.440 0.679
Year2 0.976 0.935 1.019 0.267
Constant 2.598 0.028 240.853 0.679
* P\ 0.05, ** P\ 0.001
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determinants may be measurable but not readily available
at medicine level between 2008 and 2013. For example,
inclusion of access to timely diagnosis could be measured
by looking at the average stage at which patients are
diagnosed. However, the required data for different coun-
tries is not simple to obtain, and several medicine-indica-
tion combinations and would require utilisation data by
indication. This study therefore had to limit the number of
variables included to those for which data was available at
the required level and frequency in the three study
countries.
There are a number of limitations in our study. First, it
was not possible to include incidence of different types of
cancer in the model. The majority of the medicines inclu-
ded in the sample were approved for the treatment of dif-
ferent cancer indications that are associated with different
incidence levels. Only availability of utilisation data by
ICD-10 code would have therefore enabled to link use with
incidence in a reliable way. Second, it is well-known that
list prices (e.g. British National Formulary) and undis-
counted expenditure figures do not reflect what health
payers pay for medicines [34]. Nevertheless, list prices are
still the starting point for negotiation, and the presence of
special pricing arrangements at national level is captured
by the MEA variable. Further, it would have simply been
impossible to access real discounted prices on 31 cancer
medicines in three different countries. Third, again due to
lack of data at indication level but also lack of cost-utility
estimates for all the medicines in each country, I could not
include in the model the incremental cost-effectiveness
ratio estimated for different indications in each country.
Fourth, the number of dispensed doses does not necessarily
mean that they were all consumed. Considering the high
cost of new cancer medicines and the severity of cancer, it
is unlikely that wastage will have significantly affected the
results. Fifth, I did not have access to dispensing data at
sub-national, and, therefore, could not control for differ-
ences in dispensing at that level, which may be significant.
Conclusions
Access to new medicines ought to be targeted to medicines
that bring meaningful added value to patients in compar-
ison to existing therapies. Use of medicines with modest
therapeutic improvement, mostly at higher prices than
existing treatments, draws resources away from potentially
more effective interventions. It is therefore important that
competent authorities assess added therapeutic value and
enable access to medicines with high value and limit access
to those with low value. This study showed that the most
important correlates of increased medicines utilisation in a
sample of cancer medicines introduced in the past 15 years,
were medicines coverage and time since EU marketing
authorisation. Prices had a negative effect on consumption,
meaning that they can represent a barrier for access. The
lack of a regressive effect of prices on consumption in
Scotland, and the positive impact of financial MEAs,
suggests that the latter may remove the regressive effect of
list prices on consumption. Scotland was also the only
country where low clinical added value of a medicine was
correlated with reduced consumption, suggesting that
existing entry arrangements in place, particularly HTA and
clinical guidelines, seem to guide towards use of high value
products and limiting access to low value ones. However, it
is also important to note that Scotland had the lowest level
of consumption for most medicines, raising the question as
to whether the other two countries have too generous
access requirements or whether the former’s are too
restrictive. An analysis of patient level data including di-
agnosis and prescribing information could help answering
this question.
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